Nanocarriers Mediated Cutaneous Drug Delivery
Copyright © 2020. Published by Elsevier B.V..
The cutaneous drug delivery represents an attractive option for the management of skin diseases. However, the skin has a very complex morphological structure, although the skin barrier is disrupted in some of dermatological diseases. Therefore, to safely overcome the skin barrier and to deliver drugs across the skin efficiently is still remain as a challenge in the management of dermatological diseases. The nanocarrier mediated cutaneous delivery appears to offer a hope to provide targeting potential of the drugs into specific sites of the skin with minimizing side effects. This review highlights the human structure and diseased skin barrier, and possible therapeutic outcomes of nanocarrier based drug delivery in the treatment of skin diseases due to their skin transport and follicular targeting mechanisms, and summarizes recent studies in which polymer, lipid and surfactant based nanocarriers of drugs used in the skin diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:158 |
|---|---|
| Enthalten in: |
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences - 158(2021) vom: 01. März, Seite 105638 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Güngör, Sevgi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cutaneous delivery |
|---|
| Anmerkungen: |
Date Completed 21.06.2021 Date Revised 21.06.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejps.2020.105638 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317437887 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317437887 | ||
| 003 | DE-627 | ||
| 005 | 20231225163253.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejps.2020.105638 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1058.xml |
| 035 | |a (DE-627)NLM317437887 | ||
| 035 | |a (NLM)33176190 | ||
| 035 | |a (PII)S0928-0987(20)30426-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Güngör, Sevgi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nanocarriers Mediated Cutaneous Drug Delivery |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.06.2021 | ||
| 500 | |a Date Revised 21.06.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020. Published by Elsevier B.V. | ||
| 520 | |a The cutaneous drug delivery represents an attractive option for the management of skin diseases. However, the skin has a very complex morphological structure, although the skin barrier is disrupted in some of dermatological diseases. Therefore, to safely overcome the skin barrier and to deliver drugs across the skin efficiently is still remain as a challenge in the management of dermatological diseases. The nanocarrier mediated cutaneous delivery appears to offer a hope to provide targeting potential of the drugs into specific sites of the skin with minimizing side effects. This review highlights the human structure and diseased skin barrier, and possible therapeutic outcomes of nanocarrier based drug delivery in the treatment of skin diseases due to their skin transport and follicular targeting mechanisms, and summarizes recent studies in which polymer, lipid and surfactant based nanocarriers of drugs used in the skin diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cutaneous delivery | |
| 650 | 4 | |a dermatological skin diseases | |
| 650 | 4 | |a follicular delivery | |
| 650 | 4 | |a nanocarriers | |
| 650 | 4 | |a skin delivery | |
| 650 | 4 | |a topical delivery | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 700 | 1 | |a Kahraman, Emine |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences |d 1998 |g 158(2021) vom: 01. März, Seite 105638 |w (DE-627)NLM097331937 |x 1879-0720 |7 nnns |
| 773 | 1 | 8 | |g volume:158 |g year:2021 |g day:01 |g month:03 |g pages:105638 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejps.2020.105638 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 158 |j 2021 |b 01 |c 03 |h 105638 | ||